Moxonidine treatment of hypertensive patients with advanced renal failure

Vonend, Oliver; Marsalek, Parvaneh; Russ, Hagen; Wulkow, R.; Oberhauser, Vitus; Rump, Lars Christian

doi:10.1097/00004872-200309000-00021

Cited by 89 publications

(71 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This corroborates results from a comparative study regarding tolerability of moxonidine versus nitrendipine in hypertensive patients with renal failure. 27 In this study, the decrease in creatinine clearance and the increase in serum creatinine during 24 weeks of add-on treatment were significantly lower for moxonidine than for nitrendipine.…”

Section: Discussionmentioning

confidence: 47%

Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study

2004

View full text Add to dashboard Cite

Moxonidine is a centrally active imidazoline receptor agonist that effectively lowers blood pressure and has been shown to have beneficial effects on lipid and carbohydrate metabolism. We assessed the efficacy of moxonidine in a postmarketing surveillance study (CAMUS) conducted in 772 practices in Germany, documenting 4005 patients with hypertension, who were overweight and/or suffered from metabolic syndrome. Patients were treated with moxonidine (Cynt s ) for the first time following the baseline visit for 8 weeks. Mean blood pressure decreased from 168/97 to 141/83 mmHg for all patients and from 168/96 to 141/83 mmHg for patients with metabolic syndrome. Blood pressure reduction was particularly pronounced in patients with severe hypertension at baseline. The response rate (DBPp90 mmHg or reduction X10 mmHg) of antihypertensive treatment with moxonidine was 94.0% for all patients and 93.8% for patients with metabolic syndrome. The recommended targets for antihypertensive treatment of the German Diabetes Society/German Hypertension Society were reached by 30.5% of nondiabetics (goal: o140/90 mmHg) and by 3.6% of diabetics (goal: o130/80 mmHg) observed. After 8 weeks of treatment, patients achieved a mean weight loss of 1.4 kg, which was particularly pronounced in obese patients. The rate of patients receiving antihypertensive combination therapy was 81.1% for those with metabolic syndrome, and 63.3% for all other patients. Patients with metabolic syndrome were preferentially treated with ACE inhibitors and diuretics. We conclude that moxonidine effectively reduces blood pressure in patients with metabolic syndrome while simultaneously reducing body weight in obese patients.

show abstract

Section: Discussionmentioning

confidence: 47%

Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study

2004

View full text Add to dashboard Cite

show abstract

“…8 In addition to the reduction in sympathetic nerve activity, there is evidence for a blood pressure-independent renoprotective effect of the drug as demonstrated by a reduced decline of eGFR in CKD patients when compared with an equipotent dose of a calcium channel blocker 8 and by a favorable effect on microalbuminuria in the absence of blood pressure changes in patients with type 1 diabetes mellitus and optimal blood pressure control. 9 Importantly and consistent with the data presented by Grassi et al 6 in this issue, a previous study also found that sympathetic activity remains elevated in CKD patients despite adequate The kidneys are strategically positioned to be both origin and target of increased sympathetic activation.…”

mentioning

confidence: 99%

“…Selective renal denervation as can be achieved by catheter-based application of radiofrequency energy may have additional benefit in that it not only reduces efferent sympathetic drive to the kidneys but also interferes with afferent signaling (8), thereby potentially targeting a major mediator of renal injury-induced sympathetic activation.…”

mentioning

confidence: 99%

Sympathetic Activation in Chronic Kidney Disease

Schlaich

2011

Hypertension

View full text Add to dashboard Cite

“…However, normalization of sympathetic activity can only be achieved if a central sympatholytic drug (moxonidine) is added to this treatment [62]. Moxonidine has been shown to have renoprotective properties in chronic renal failure and to reduce MSNA [63,64]. This effect was independent from blood pressure reduction.…”

Section: Pharmaceutical Approachmentioning

confidence: 99%